■MEDIPOST announced on the 29th that it participated in 'BIO Asia-Taiwan 2025' held in Taipei, Taiwan, from 23rd to 27th. This event is the largest annual biotechnology event in the Asia-Pacific (APAC) region. Through this conference participation, MEDIPOST aimed to inform about its capabilities as a total solution provider in the area of umbilical cord blood stem cells and has commenced its entry into the Asian market. In particular, it focused on introducing its integrated solution capabilities established across all areas, including the development of stem cell therapies starting from the umbilical cord blood banking business, domestic commercialization achievements, global clinical development of CATIS, and CDMO business.
■Hallym University Kangnam Sacred Heart Hospital announced on the 29th that a research team led by Professor Kim Hyung-nyeon succeeded in applying a groundbreaking treatment method for exudative wounds around the ankle, accomplishing complex wound suturing. The ankle area is characterized by a thin fatty layer beneath the skin and the tendons and bones being easily exposed, which results in wounds not healing properly and easily reopening. In particular, if synovial fluid or tendon sheath lubricant continually drains, it washes away the tissue cells needed for wound healing, leading to non-healing wounds and a high risk of infection. The treatment method developed by the research team involves maintaining a suction drainage tube inserted at the wound site for a long period (typically 9 to 16 days, with an average of about 14 days) post-surgery, applying continuous negative pressure to expel fluids, blood, pus, and so on. As a result of the study, 95% of all patients (19 individuals) were completely healed without skin grafting from other areas of skin or muscle covering the Achilles tendon, and there were no cases of infection. In the case of repeat sutures, the team introduced ultrasound-guided peripheral nerve block anesthesia instead of general or spinal anesthesia to reduce patient burden.
■GC Biopharma announced on the 29th that it held a researcher-led symposium on the clinical usefulness of 'Rosetel' and 'Rosetelpine' at the Parnas Hotel in Seoul on the 26th and 27th. The symposium introduced interim results from an observational study of 'Rosetel'. The study was conducted on patients receiving treatment for hypertension and dyslipidemia following percutaneous coronary intervention (PCI) and evaluated the efficacy and safety at the 24-week and 48-week points. The intermediate analysis showed a notable result, with an improvement of approximately 27% in the proportion of patients meeting both blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) targets compared to before treatment at the 24-week point. Further analysis of the individual figures also indicated a trend of increasing target achievement rates for both items, validating the clinical value of the combined medication strategy for heterogeneous diseases.
■Ilsan Byungbyun Hospital announced on the 29th that it has introduced a large number of certified domestic artificial intelligence (AI) technologies in the emergency room and intensive care unit. Representative solutions introduced by the hospital include the cardiac arrest prediction system 'DeepCAS', the brain hemorrhage diagnostic assist AI 'AIVUE NeuroCAD', a system for evaluating blood flow function 'Heart Medi Plus', and a technology for analyzing electrocardiograms to analyze cardiac function abnormalities 'ECG Buddy'. These solutions support real-time decision-making for medical staff and enhance the accuracy of diagnoses, enabling quicker responses. All of these solutions are certified as 'new medical technologies' by the Ministry of Health and Welfare. Ilsan Byungbyun Hospital stated that it will continue to introduce AI and digital technologies to establish a patient-centered medical environment that sets a new standard for treating critically ill patients in the northwestern Gyeonggi region.
■GeoYoung announced on the 29th that it is conducting a 'Hot Summer Cold Chain Event' at its nationwide logistics centers to support delivery drivers who are responsible for pharmaceutical supply, even in the sweltering summer heat. This event is part of a summer support activity aimed at promoting health management and strengthening on-site relationships for delivery drivers working in high-temperature environments, providing items such as ice water at various logistics centers on a regular basis. GeoYoung Chairwoman Cho Sun-hye expressed her gratitude for the efforts of the logistics headquarters and delivery team leaders who continuously support the field amid the heat. She noted, "The distribution of pharmaceuticals is the foundation of protecting public health and is part of our social responsibility. We will continue to provide practical support for our field personnel under this awareness."
■CLASSYS announced on the 29th that it is accelerating its global market expansion based on support from the Korean Intellectual Property Office. CLASSYS CEO Baek Seung-han discussed strategies for export support and intellectual property protection for K-medical aesthetic corporations with Korean Intellectual Property Office Commissioner Kim Wan-ki during his visit to CLASSYS headquarters on the 25th. On that day, CEO Baek requested the Korean Intellectual Property Office to strengthen its ongoing support policies to ensure that the technological and brand assets of export-leading companies are securely protected overseas. CLASSYS leads the industry with its unrivaled technology in the energy-based device (EBD) sector and is among the companies with the most patents in the domestic medical device field. The number of intellectual property applications by CLASSYS increased by 50%, from 1,145 cases in 2022 to 1,718 cases as of March this year. The number of registered cases also significantly grew from 781 to 1,169 during the same period.
■SD BIOSENSOR announced on the 29th that it successfully conducted symposiums and exhibition booths as a platinum sponsor at 'TECA 2025' held in Kampala, Uganda, from the 21st to the 23rd of this month. TECA 2025 is a pan-African health academic conference aimed at discussing cooperation and execution strategies for ending mother-to-child transmission (EMTCT) of HIV, syphilis, and hepatitis B by 2030. The company presented a topic titled 'Simultaneous Diagnosis of HIV, Syphilis, and Hepatitis B with One Kit: Strategic Approach to Achieving WHO's Mother-to-Child Transmission Elimination Goal'.
■Korea BMS Pharmaceuticals announced on the 29th that it is recruiting participants for the 8th round of its self-support program 'Reboot' for low-income young cancer patients, which will run from August 1 to September 10. Reboot provides employment, education, cultural, and emotional support for young cancer patients who have completed active cancer treatment, creating opportunities for social reintegration and supporting emotional recovery. This program has been operated for the eighth year, based on voluntary donations from employees and company contributions, with the Milal Welfare Foundation in charge of its implementation. In the 8th round of Reboot, 11 low-income vulnerable individuals aged 19 to 39, who have completed initial aggressive treatment such as surgery, chemotherapy, and radiation, will be selected based on the median income being under 80%. Interested applicants can download the application form from the Milal Welfare Foundation's website and submit it via email within the designated period.